Objective and design Most cases of euvolaemic hyponatraemia are associated with elevated plasma levels of AVP. Conivaptan is a high-affinity, nonpeptide vasopressin V1A/V2-receptor antagonist. We performed a subgroup analysis of a multicentre, randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous (i.v.) conivaptan for the treatment of euvolaemic hyponatraemia.
Patients Fifty-six euvolaemic patients with serum [Na+] of 115 to < 130 mmol/l received conivaptan 40 or 80 mg/day or placebo via continuous i.v. infusion for 4 days. A 20-mg loading dose was administered intravenously over 30 min in the conivaptan groups; the placebo group received a placebo loading dose.
Measurements Change in serum [Na+], measured by the baseline-adjusted area under the serum [Na+]–time curve (AUC), was the primary efficacy parameter. Secondary efficacy measures included the time from the first dose to a confirmed ≥ 4 mmol/l increase in serum [Na+], total time with serum [Na+] ≥ 4 mmol/l above baseline, change in serum [Na+] from baseline, and number of patients with a confirmed ≥ 6 mmol/l increase in serum [Na+] or normal [Na+]. Safety assessments included adverse events (AE), incidence of overly rapid correction of serum [Na+], and changes in vital signs and electrocardiographic and clinical laboratory parameters.
Results During the first 2 days of treatment, and over the entire 4-day treatment period, both conivaptan doses significantly increased the serum [Na+] AUC more than placebo (P < 0·01). Conivaptan 40 and 80 mg/day significantly improved all secondary efficacy measures. Conivaptan was generally well tolerated; infusion-site reaction was the most common AE.
Conclusions In hospitalized patients with euvolaemic hyponatraemia, i.v. conivaptan significantly increased serum [Na+] promptly and was well tolerated.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.